ABSTRACT
BACKGROUND: Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most common. Treatment, which has no definitive cure, aims for complete resolution of skin symptoms and depends on disease extent, severity, and impact on patients' lives. Biologics are an emerging treatment for psoriasis, targeting specific inflammatory pathways for potentially safer, more effective outcomes. However, these come with significant costs, necessitating more research to ensure value for money. This study aimed to compare the effectiveness of Risankizumab versus Adalimumab, the most commonly utilized biologic for managing psoriasis in Saudi Arabia. METHODS: This study retrospectively compared the effectiveness and direct medical cost of Risankizumab and Adalimumab in treating chronic plaque psoriasis in adults from two Saudi Arabian healthcare centers. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) were used to assess treatment effectiveness, with patient data sourced from electronic medical records. Multiple regression analysis was performed to examine various factors affecting treatment outcomes. An economic evaluation was conducted to examine the cost-effectiveness of the two drugs, considering four scenarios with varying dosage patterns and costs. Analysis was performed from the perspective of public healthcare payers and considered all utilized health services. RESULTS: The data for 70 patients were analyzed, with comparable baseline characteristics between groups. While Risankizumab led to a greater reduction in PASI scores and BSA affected, these results were not statistically significant. The annual treatment cost for Risankizumab was higher than Adalimumab. Various scenarios were studied, considering real acquisition costs, double dosing for Adalimumab, and the use of biosimilars. A scenario assuming double dosing for Adalimumab and a 40% discount for Risankizumab demonstrated both cost and efficacy advantages in 71.25% of cases. CONCLUSIONS: This study compared the effectiveness and cost of Risankizumab and Adalimumab for treating chronic plaque psoriasis in Saudi Arabian hospitals. Although Risankizumab showed a greater reduction in symptoms, the difference was not statistically significant. However, under certain scenarios, Risankizumab demonstrated cost and efficacy advantages. These findings may influence treatment decisions for psoriasis, but further research is needed.
ABSTRACT
Objectives: This study aims to determine the sociodemographic characteristics of pet owners and their sources of information regarding pet-related health risks. It also assesses pet owners' perception of pet-related health risks and evaluates their attitudes and practices regarding preventative measures toward pet-related health risks. Methods: A cross-sectional study was conducted in Riyadh, Saudi Arabia from September 2020 to February 2021. The target population was pet owners visiting pet stores. The city was divided into five equal sectors and data were collected from each sector using a questionnaire. Results: A total of 508 participants were engaged in the study. Of these, 402 participants fit the inclusion criteria. The mean age of the participants was 25.5 years. Gender was almost equally distributed, and the majority of participants were single, however most of the participants lived with four or more family members. Around 49.5% of participants had household members at a higher risk for pet-related diseases. The most common pet types were cats (77.4%), followed by birds (24.6%) and dogs (9.7%). Most participants were satisfied with their understanding of pet-related health risks and were not concerned about getting sick because of contact with pets. Physical harm was the most common pet-related health risk that the participants were satisfied with their level of understanding about, on the other hand their satisfaction with their understanding about gastrointestinal infections from pet contact was the lowest. Most participants had good pet husbandry and hygiene practices. Social media and veterinarians were the most common sources of information regarding pet-related health risks. Conclusion: Although most pet owners reported having good pet husbandry practices, further education is needed to raise awareness about pet-related health risks. Since most pet owners receive their information about this topic from social media and veterinarians, further education through these platforms might be beneficial.
